

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Graham Charles Bloomfield et al.

Serial No.: 10/568,053 Group Art Unit: 1626

Filed: June 18, 2008 Examiner: Laura L. Stockton

For: 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS  
INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES  
(PI13) FOR TREATMENT OF INFLAMMATORY DISEASES

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56 AND §1.97(b)(3)**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:


The citation listed on the enclosed Supplemental Information Disclosure Form PTO/SB/08a may be material to the examination of the above-identified patent application. Therefore, Applicants submit this document in compliance with the duty of disclosure as defined in 37 C.F.R. §1.56 and §1.97(b)(3). The Examiner is requested to make this citation of official record in the present application.

This Supplemental Information Disclosure Statement under 37 CFR §1.56 and §1.97(b)(3) is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that this citation constitutes prior art under 35 USC §102 or §103.

Since the present Supplemental Information Disclosure Statement is being filed after the mailing date of the first Office Action, the Commissioner is hereby authorized to charge the \$180.00 fee under 37 CFR 1.17(p) or any additional fees in connection with this Supplemental Information Disclosure Statement to Deposit Account No. 50-4409.

Respectfully submitted,

By:

  
\_\_\_\_\_  
Vinit Kathardekar  
Attorney for Applicants  
Reg. No. 39,461

February 23, 2010

NOVARTIS VACCINES AND DIAGNOSTICS, INC.  
Intellectual Property – X-100B  
P.O. Box 8097  
Emeryville, California 94662-8097  
(510) 923-3949  
(510) 655-3542 (fax)